These strategies promote the identification of potentially rational target combinations of dual-target VEGFR inhibitors via predicting structural similarity between active sites of VEGFR and other tumor-related targets or reliable analyses of relevant signaling pathways. This evidence concerns the gene KDR and neoplasm.